EGFR mutation

EGFR 20ins Mutation Lung Cancer: ADC and Immunotherapy Redefining ‘Hard-to-Treat’

by
EGFR 20ins Mutation Lung Cancer: ADC and Immunotherapy Redefining 'Hard-to-Treat'

Click the arrow to follow us with the “blue text”! 1. 20ins Mutation: The ‘Hard-to-Treat Code’ of the EGFR Family The EGFR exon 20 insertion (20ins) mutation accounts for 4%-12% of NSCLC. Due to the unique mutation site, traditional EGFR-TKIs (such as gefitinib and osimertinib) struggle to bind effectively, leading to its classification as a … Read more

The Global Breakthrough of TROP2 ADC for Lung Cancer: A Chinese Innovative Drug Reshaping the Treatment Landscape for EGFR-Mutated Lung Cancer

by
The Global Breakthrough of TROP2 ADC for Lung Cancer: A Chinese Innovative Drug Reshaping the Treatment Landscape for EGFR-Mutated Lung Cancer

Compiled by: Oncology NewsSource: Oncology News In the field of lung cancer treatment, patients with EGFR-mutated non-small cell lung cancer (NSCLC) have long faced a “treatment desert” after developing resistance to TKI therapy, with traditional chemotherapy offering limited efficacy and significant side effects. The Chinese innovative drug, sacituzumab tirapazamine, developed by Professor Zhang Li’s team, … Read more